A novel autocrine pathway of tumor escape from immune recognition: Melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage Melan-A/MART-1 antigen through down-modulation of its promoter

Journal of Immunology

Volumn 167, Issue 3, 2001, Pages 1204-1211

  Kurnick, J T ^a   Ramirez Montagut, T ^a   Boyle, L A ^a   Andrews, D M ^a   Pandolfi, F ^a   Durda, P J ^a   Butera, D ^a   Dunn, I S ^a   Benson, E M ^a   Gobin, S J P ^a   Van den Elsen, P J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; MELAN A; TUMOR PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; AUTOCRINE EFFECT; CELL LINEAGE; CYTOTOXIC T LYMPHOCYTE; GENE SILENCING; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; MELANOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; SUPERNATANT; T LYMPHOCYTE; TUMOR CELL CULTURE; TUMOR ESCAPE; TUMOR GROWTH;

EID: 0035422746     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.3.1204     Document Type: Article

References (49)

1. Accumulation of the same anti-melanoma T cell clone in two different metastatic sites
2. Tumor antigens recognized by T lymphocytes
3. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
4. Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy
5. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: Fine specificity and MART-1 melanoma antigen recognition
6. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
7. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy
8. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer
9. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy
10. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma: A national biotherapy study group trial
11. Use of tumor-infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma
12. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
13. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
14. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with down-regulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen
15. Recognition of melanoma-derived antigens by CTL: Possible mechanisms involved in down-regulating anti-tumor T-cell reactivity
16. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
17. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
18. Differential expression of MART-1 in primary and metastatic melanoma lesions
19. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo
20. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions
21. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: A study in an unselected group of HLA-A2.1-positive patients
22. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: Autoimmune nature of the anti-melanoma CTL response
23. Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma
24. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition
25. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors
26. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
27. In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumor-cell variants expressing a single HLA-class-I allele
28. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors
29. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells
30. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy
31. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation
32. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription
33. Heterogeneous expression of immunotherapy candidate proteins gp100. MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions
34. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response
35. Melanoma-antigen recognition by tumor infiltrating T lymphocytes (TIL): Effect of differential expression of Melan-A/MART-1
36. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas
37. T311: An anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues
38. Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions
39. Antigen processing and presentation by human trophoblast-derived cell lines
40. Frequency of clonally expanded T cells evaluated by PCR from a single cell
41. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes
42. Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not co-regulated
43. Heterogeneity of cytokine and growth factor gene expression in human melanoma cells with different metastatic potentials
44. Heterogeneity of cytokine production by human malignant melanoma cells
45. Interleukin-6 production and secretion in human melanoma cell lines: Regulation by interleukin-1
46. Production of multiple cytokines by cultured human melanomas
47. Autocrine and paracrine regulation by cytokines and growth factors in melanoma
48. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells
49. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma